Curis, Inc. (Nasdaq: CRIS) announced that it has re-initiated dosing in the single-agent clinical trial of CUDC-427 in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE